|
|
|
AFRICA: MSF pressures Abbott on key ARV
[This report does not necessarily reflect the views of the United Nations]
JOHANNESBURG, 28 April (PLUSNEWS) - US drug giant Abbott Laboratories was on Thursday accused of withholding new heat-resistant tablet versions of its anti-AIDS drug Kaletra in developing countries.
International medical NGO, Medecins San Frontieres (MSF), said current refrigerated liquid versions of the drug being used in resource-limited settings, was creating treatments hurdles.
MSF president Rowan Gillies said in a statement: "... where refrigerators are a luxury, [Kaletra] is urgently needed by patients switching to second-line AIDS treatment. How can Abbott continue to drag its feet in filing for registration in most African countries?"
Kaletra is a key second-line treatment that is used after HIV-positive people naturally develop resistance to first-line combinations.
[ENDS]
:: MORE NEWS BRIEFS ::
|
|
|
|
|
|
|
| Links |
· AIDS Media Center
|
· The Global Fund to fight AIDS, Tuberculosis & Malaria
|
· International Community of Women Living with HIV/AIDS
|
· AEGIS
|
· International HIV/AIDS Alliance
|
PlusNews does not take responsibility for info in links supplied.
|
|
|
|
|
[Back] [Home Page]
Click here to send any feedback, comments or questions you have about PlusNews Website or if you prefer you can send an Email to Webmaster
Copyright © IRIN 2006
The material contained on www.PlusNews.org comes to you via IRIN, a UN humanitarian news and information service, but may not necessarily reflect the views of the United Nations or its agencies.
All PlusNews material may be reposted or reprinted free-of-charge; refer to the IRIN copyright page for conditions of use. IRIN is a project of the UN Office for the Coordination of Humanitarian Affairs.
|
